Literature DB >> 16763865

[(Side) effects of VEGF inhibition].

F Ziemssen1, K U Bartz-Schmidt, S Grisanti.   

Abstract

Vascular endothelial growth factor (VEGF) plays a pivotal role for embryo- and organogenesis. By regulating haemodynamics, (lymphoid) vessel architecture, haematopoiesis and immune system, endocrinology and reparative processes in adults, inhibited VEGF can cause multiple adverse events. Although the intravitreal administration of smaller doses can drastically reduce the systemic exposure, possible local side effects on retinal perfusion and survival of neuronal tissue must be taken into consideration. Before experience has been gained with VEGF inhibitors for longer than several years, individual discussion before the use, extensive informed consent and careful follow-up are necessary. From the ethical point of view, the available drugs should not be used without hesitation despite the clear benefit. First experiences with bevacizumab (Avastin), the first available (off-label) drug in Germany, are reported. In future, direct comparison of the different available drugs has to assess possible differences in the risk-benefit profile.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763865     DOI: 10.1007/s00347-006-1354-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  76 in total

Review 1.  Continuing medical education review: choroidal neovascularization in age-related macular degeneration--what is the cause?

Authors:  Richard F Spaide; Donald Armstrong; Richard Browne
Journal:  Retina       Date:  2003-10       Impact factor: 4.256

2.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

Review 3.  Ocular versus extraocular neovascularization: mirror images or vague resemblances.

Authors:  Peter A Campochiaro
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-02       Impact factor: 4.799

Review 4.  Manipulation of ovarian follicle development by injecting vascular endothelial growth factor (VEGF) gene.

Authors:  Takashi Shimizu; Eimei Sato
Journal:  Reprod Biol       Date:  2005-11       Impact factor: 2.376

5.  Bevacizumab, bleeding, thrombosis, and warfarin.

Authors:  Saadettin Kilickap; Huseyin Abali; Ismail Celik
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

6.  Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function.

Authors:  Alexander G Marneros; Jie Fan; Yoshihito Yokoyama; Hans Peter Gerber; Napoleone Ferrara; Rosalie K Crouch; Bjorn R Olsen
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

7.  Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.

Authors:  Raj K Maturi; Laura A Bleau; Donald L Wilson
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

8.  Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary.

Authors:  N Ravindranath; L Little-Ihrig; H S Phillips; N Ferrara; A J Zeleznik
Journal:  Endocrinology       Date:  1992-07       Impact factor: 4.736

9.  VEGF(165) mediates glomerular endothelial repair.

Authors:  T Ostendorf; U Kunter; F Eitner; A Loos; H Regele; D Kerjaschki; D D Henninger; N Janjic; J Floege
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

10.  Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.

Authors:  E A Pierce; E D Foley; L E Smith
Journal:  Arch Ophthalmol       Date:  1996-10
View more
  12 in total

1.  [Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks].

Authors:  A Lommatzsch; G Spital; M Trieschmann; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

Review 2.  [Intravitreal injection. Monitoring to avoid postoperative complications].

Authors:  C H Meyer; F Ziemssen; H Heimann
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

Review 3.  [Diabetic maculopathy. Diagnosis and treatment].

Authors:  F Gelisken; F Ziemssen
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

4.  Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?

Authors:  Focke Ziemssen; Bianka Sobolewska
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

5.  [Retinochoroidopathy after intravitreal anti-VEGF treatment].

Authors:  M Maier; N Feucht; I Lanzl; P Kook; C P Lohmann
Journal:  Ophthalmologe       Date:  2009-08       Impact factor: 1.059

6.  [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Authors:  D Kook; A Wolf; A S Neubauer; C Haritoglou; S G Priglinger; A Kampik; M W Ulbig
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

7.  [Primary vitrectomy with intraocular antibiotic application in postoperative endophthalmitis].

Authors:  M Rehak; R Blatz; P Wiedemann; P Meier
Journal:  Ophthalmologe       Date:  2007-11       Impact factor: 1.059

Review 8.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum.

Authors:  Martin Ganssauge; Helmut Wilhelm; Karl-Ulrich Bartz-Schmidt; Sabine Aisenbrey
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12       Impact factor: 3.117

10.  [Antiangiogenic therapy for pterygium recurrence].

Authors:  S Leippi; F Grehn; G Geerling
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.